• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ther­a­vance cuts 17% of staff, JAK in­hibitor pro­gram

3 years ago
People
R&D

Decades af­ter break­through, sci­en­tists still puz­zling over mR­NA de­liv­ery

3 years ago
R&D
In Focus

Suf­fer­ing CNS play­er flips an­oth­er los­ing hand in a last PhII gam­ble and calls for the axe

3 years ago
R&D

As­traZeneca ex­pands Cana­da R&D work, to add 500 jobs

3 years ago
R&D
Pharma

Jazz los­es ap­peal, will have patent delist­ed from the Or­ange Book

3 years ago
Pharma
Law

UK biotech hands off mid-stage C. dif­fi­cile drug in up to $570M deal

3 years ago
Deals

Gay men's health group and ad agency part­ner say FDA blood do­na­tion pro­pos­al 'still falls short'

3 years ago
Pharma
Marketing

State at­tor­neys gen­er­al sue FDA over abor­tion pill ac­cess re­stric­tions

3 years ago
R&D
Law

Ac­tivist in­vestor push­es for man­age­ment over­haul, strate­gic re­view at Ther­a­vance

3 years ago
People

Eye­Point and Rally­bio shake hands on col­lab­o­ra­tion; Sh­iono­gi ex­pects bil­lions for Covid an­tivi­ral pill — re­port

3 years ago
News Briefing

Tiny Apex­i­gen to lay off ma­jor­i­ty of work­ers af­ter SPAC deal

3 years ago
People

FDA neu­ro­science chief Bil­ly Dunn, who led Aduhelm ap­proval, will leave agency

3 years ago
Pharma
FDA+

Ax­some says FDA wants more da­ta for Alzheimer’s ag­i­ta­tion la­bel ex­pan­sion, but read­out to come soon­er 

3 years ago
R&D
FDA+

Who’s chart­ing paths for LGBTQ+ lead­ers in bio­phar­ma? Nom­i­nate them for End­points’ an­nu­al re­port

3 years ago
People

Ahead of FDA de­ci­sion, Blue­print puts out full da­ta for ex­pand­ed Ay­vak­it la­bel

3 years ago
R&D

Glen­mark's biotech com­pa­ny Ich­nos Sci­ences lays off 50

3 years ago
People

Pfiz­er spin­out Spring­Works gets FDA pri­or­i­ty re­view for lead drug

3 years ago
FDA+

Dr. Red­dy's to buy Mayne Phar­ma’s US gener­ics drug list for at least $90M

3 years ago
Deals
Pharma

Pfiz­er makes moves to ac­quire Seagen in po­ten­tial $30B+ deal

3 years ago
Deals
Pharma

Com­pa­nies flail amid broad biotech fall­out; Sick­le cell reck­on­ing; Fol­low-up on Pfiz­er's CRO trou­ble; and more

3 years ago
Weekly

Eu­ro­pean reg­u­la­tors rec­om­mend re­jec­tion of Mer­ck’s Covid-19 drug mol­nupi­ravir

3 years ago
Pharma
Coronavirus

Pfiz­er's Paxlovid gets March FDA ad­vi­so­ry meet­ing to dis­cuss full ap­proval

3 years ago
Pharma
Coronavirus

GSK's bell­wether Zan­tac court date pushed to Ju­ly

3 years ago
Pharma
Law

As­traZeneca pulls back the cor­po­rate cur­tain to high­light re­al peo­ple and chat com­plex sci­ence

3 years ago
Pharma
Marketing
First page Previous page 370371372373374375376 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times